Clinical trials: MDS (Myelodysplastic Syndrome)
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia
- Trial name
- NCT03849651
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Adult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or blastic plasmocytoid dentritic cell neoplasm will be…
- Conditions
- Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic Syndromes (MDS), Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Trial name
- UHKT-CAR123-01 (NCT06765876)
- Testing
- Autologous CAR123 T lymphocytes
- Where
- Czechia
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
MDS (Myelodysplastic Syndrome)
Luspatercept + Darbepoetin in MDS
This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level < 500 IU/L.
- Trial name
- DarbeLus (NCT07096297)
- Testing
- Luspatercept, Darbeopoetin
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Acute Leukemia, Acute Lymphoblastic Leukemia
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain…
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT05589896
- Testing
- Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC)
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ossium Health, Inc.
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS)
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Background: Severe aplastic anemia (SAA), and myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) cause serious blood problems.
- Conditions
- Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Trial name
- NCT03520647
- Testing
- Cyclophosphamide, Peripheral Blood Stem Cells
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.
- Trial name
- NCT05568225
- Testing
- Etavopivat
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 17 people
- Sponsor
- Forma Therapeutics, Inc.
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously.
- Trial name
- PyramIDH (NCT06465953)
- Testing
- Ivosidenib, Azacitidine
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 48 people
- Sponsor
- Institut de Recherches Internationales Servier
AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation.
- Trial name
- RELEVANT (NCT07025824)
- Testing
- Treosulfan (Treo), Melphalan (Mel), Fludarabine (Flud)
- Where
- 17 sites in Germany
- Volunteers
- 220 people
- Sponsor
- Technische Universität Dresden
MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Dresden MDS Registry With an Accompanying Biomaterial Collection
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP…
- Conditions
- MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, CHIP, CCUS Clonal Cytopenia of Undetermined Significance
- Trial name
- NCT07561385
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT
To explore the safety and efficacy of selinexor combined with azacitidine as post-transplant maintenance therapy for TP53-mutated AML/MDS.
- Trial name
- TP53 (NCT07779031)
- Testing
- Azacitidine (AZA) Days 1 - 5, Selinexor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Liping Dou
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS
- Trial name
- MORE (NCT05796570)
- Testing
- Decitabine, Filgrastim
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Franziska Wachter
Leukemia, Lymphoma
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS)
- Trial name
- PROACTIVE (NCT04898790)
- Testing
- CHAMPS-II adapted to adults 60+ years in HCT setting
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Nebraska
Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
- Trial name
- NCT06656494
- Testing
- ICP-248, Azacitidine
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 266 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic…
- Conditions
- Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS)
- Trial name
- NCT07565220
- Testing
- Thiotepa, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sawa Ito, MD
Myelodysplastic Syndromes, MDS
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
This study will be conducted as a phase 1/2 study of safety and preliminary efficacy of pacritinib in combination with azacitidine for IPSS-M moderate low to very high risk MDS.
- Conditions
- Myelodysplastic Syndromes, MDS, Myelodysplastic Syndrome, Unclassifiable, Hematologic Diseases
- Trial name
- MDS (NCT07387354)
- Testing
- Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate
- Sponsor
- Thomas Jefferson University
Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are highly heterogeneous myeloid malignancies where few effective targeted therapies are available.
- Trial name
- NCT07761533
- Testing
- PBSS1113
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chaser Therapeutics, Inc.
Myelodysplastic Syndromes (MDS)
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a…
- Trial name
- NCT02942290
- Testing
- Azacitidine, Venetoclax
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 134 people
- Sponsor
- AbbVie
Myelodysplastic Syndrome (MDS)
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
[Tolerability Assessment Part] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2.
- Trial name
- NCT04608110
- Testing
- ASTX030 (AZA + CED)
- Where
- 10 sites in Japan
- Volunteers
- 59 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
- Conditions
- B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma
- Trial name
- NCT05092451
- Testing
- Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center